At this time, it is uncertain how participating beneficiaries will be able to maintain Medicare coverage of their GLP-1 medication for obesity after the Medicare GLP-1 Bridge ends at the end of 2027, pending further action from CMS to implement the BALANCE Model in Medicare Part D in 2028, as described below
GLP-1 medications (semaglutide and tirzepatide) are injected under the skin (subcutaneous), not into muscle Compounded GLP-1 medications come in multi-dose vials and require a syringe for accurate dosing Correct dosing is critical using a GLP-1 dose-to-units calculator helps prevent common mistakes The abdomen is the most commonly used injection site, but the thigh and upper arm are also safe options Rotate injection sites weekly to reduce irritation and improve medication absorption Always clean the injection site and remove air bubbles before injecting Never use medication that has been exposed to heat, sunlight, or freezing temperatures (especially important in Florida) Follow your healthcare providers instructions for dosing, storage, and injection technique GLP-1 medications are injectable treatments used for weight loss and metabolic support
Curr Nutr Rep 13(3):500515 [DOI] [PMC free article] [PubMed] [Google Scholar] 36.Breen L, Phillips SM (2011) Skeletal muscle protein metabolism in the elderly: interventions to counteract the anabolic resistance of ageing
Vitamin D : Often considered when lab levels, sun exposure, or dietary intake are low
The absolute risk is low but the condition is serious enough that patients need to know the warning signs and act on them promptly
